Skip to main content

COVID-19 and rheumatic disease

Latest news, guidance, and expert opinion for rheumatology professionals
Spotlight on: COVID-19 in rheumatic disease patients

Connective tissue disease may be risk factor for severe COVID-19

Close up of patient connected to medical ventilator in ICU

Among people with inflammatory rheumatic diseases and SARS-CoV-2 infection, having a connective tissue disease, but not inflammatory arthritis, is associated with an increased risk for severe COVID-19, Spanish researchers report.

Spotlight on: Repurposing rheumatology drugs for COVID-19

‘Inconclusive’ evidence for the use of rheumatology drugs to treat COVID-19

Question mark

Findings from a systematic review and meta-analysis suggest that hydroxychloroquine is not associated with benefits or harms in terms of COVID-19 mortality, and more studies are needed to establish whether other rheumatology drugs could be used to treat the disease.

Spotlight on: Repurposing rheumatology drugs for COVID-19

IL-6 inhibitors show potential for COVID-19

Doctor and needle

Add-on treatment with an IL-6 receptor inhibitor warrants further investigation for patients with severe COVID-19 pneumonia and systemic hyperinflammation, suggest preliminary findings from two Italian observational studies published in the Annals of the Rheumatic Diseases.

Guidance for rheumatologists

Guidance and expert opinion on rheumatology practice during the COVID-19 pandemic

COVID-19 in rheumatic disease patients

The latest research, announcements, and expert interviews on COVID-19 in patients with rheumatic diseases

Repurposing rheumatology drugs for COVID-19

The latest research and announcements on repurposing rheumatology drugs for the treatment of COVID-19

Keep up with podcasts on this topic, available on

Image Credits